Unique, practical knowledge for nurses responsible for daily management of patients with cardiovascular disease, diabetes and related conditions.

Introducing dapagliflozin for type 2 diabetes

Publication date: Friday, 07 December 2012
Contributor(s): Sandra Waddingham

Dapagliflozin (Forxiga) is the first in a new class of oral antidiabetic drug that has been given the go-ahead for marketing in Europe, including the UK. Described as a sodium glucose cotransporter 2 (SGLT2) inhibitor, this new preparation works on the kidneys to lower blood glucose. What does this new drug have to offer and how can it potentially help our patients with type 2 diabetes?

Topics covered:
Category: Editorial
Edition: Volume 9, Number 4, Oct-Nov-Dec 2012
Print edition page(s): 162-164
Contributor(s): Sandra Waddingham

Article search and filter